A recent study suggests that a commonly prescribed type of blood pressure medication, known as angiotensin receptor blockers ...

A recent study from Columbia University has raised important questions about the medications used to treat high blood ...

Dimerix has achieved a key milestone in its ACTION3 phase III trial of lead asset DMX-200 into focal segmental ...

"Beta-blockers for non-essential conditions such as high blood pressure should not be used as a first line drug," Dr Gupta said. He added that the IPC alert was issued only as an advisory and ...

placebo-controlled study of the efficacy and safety of DMX-200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor blocker (ARB). Planned blinded interim data ...

It has been assumed that the actions of the renin-angiotensin system in the brain and periphery arise from the interaction of Ang II with its receptors ... with vehicle (n=36), the AT 1 receptor ...

Abstract We investigated the effects of angiotensin ... feedback Ang II receptor in hypertensive patients produces modest increases of plasma renin activity and Ang II that do not appear to affect the ...

The best ad blockers are the perfect solution for boosting your browser speed, block pop-ups and reduce advertising from collecting data through invasive cookies. Some services will even help ...

Led by Paul Mescal, Gladiator II follows Lucius, who is forced to enter the infamous Colosseum after his home is conquered by the emperors who now lead Rome. Mescal is joined by an all-star ...

This phase III trial is a randomised, double-blind, placebo-controlled study of the efficacy and safety of DMX200 in patients with FSGS who are receiving a stable dose of an angiotensin II receptor ...

Alpha-1 adrenergic receptor antagonist (α1-ARA) are well established treatment for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS). Since BPH and erectile dysfunction ...

The UK government has announced an indefinite ban on the use of puberty blockers for treating under 18s with gender dysphoria, after the Commission on Human Medicines advised that continuing to allow ...